Onychomycosis and tinea pedis in patients with diabetes

Phoebe Rich

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Severe LE bacterial infection with resultant amputation in persons with diabetes is costly both in terms of health care use and loss of productivity from morbidity, mortality, and disability. Although there are no long-term prospective studies that prove onychomycosis treatment prevents serious sequelae, common sense suggests that preserving the cutaneous integrity of the LE is useful for the compromised patient with diabetes. A recent study shows that oral agents such as terbinafine can effectively treat and cure onychomycosis and concomitant skin infection (dermatophytosis) in patients with diabetes. The cost savings from prevention of LE complications is significant, making the expense and effort needed to treat onychomycosis and tinea pedis in patients with diabetes a sound investment. LE amputation in individuals with diabetes is the primary cause of disability and death in this population. Education of such patients about the importance of foot and nail care is paramount.

Original languageEnglish (US)
Pages (from-to)S130-S134
JournalJournal of the American Academy of Dermatology
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Onychomycosis and tinea pedis in patients with diabetes'. Together they form a unique fingerprint.

Cite this